Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and cabazitaxel pharmacokinetic combination study in metastatic castration-resistant prostate cancer
NL-OMON41753Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of enzalutamide and cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Erasmus MC. Primary endpoint: Influence of enzalutamide on cabazitaxel AUC. Started Apr 2015; status: active, not recruiting.
02
Drugs
enzalutamidecabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON41753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41753.